open access

Vol 16, No 2 (2020)
Case report
Published online: 2020-05-15
Get Citation

Long-term complete remission of pancreatic cancer after first-line chemotherapy with gemcitabine and nab-paclitaxel in a patient with depressive disorder

Ewa Anna Kosakowska, Anna Cencelewicz-Lesikow, Jakub Pałucki, Michał Kunkiel, Agnieszka Jagiełło-Gruszfeld
DOI: 10.5603/OCP.2020.0016
·
Oncol Clin Pract 2020;16(2):83-86.

open access

Vol 16, No 2 (2020)
CASE REPORT
Published online: 2020-05-15

Abstract

The article presents the case of a 64-year-old pancreatic cancer patient with complete remission of hepatic metastases after first-line chemotherapy with gemcitabine and nab-paclitaxel. Partial regression of metastatic tumours in the liver was achieved after three months of therapy, and after three more months complete remission was achieved. Grade 4 neutropaenia was reported once during the treatment. The patient was temporarily reluctant to start treatment. Better cooperation was achieved after using psychotherapy. The following case confirms the impact of the patient’s mental condition on the treatmentinitiation. The possibility of obtaining long-term complete remission in advanced pancreatic cancer — a disease with poor prognosis — following the use of gemcitabine and nab-paclitaxel-containing chemotherapy is documented.

Abstract

The article presents the case of a 64-year-old pancreatic cancer patient with complete remission of hepatic metastases after first-line chemotherapy with gemcitabine and nab-paclitaxel. Partial regression of metastatic tumours in the liver was achieved after three months of therapy, and after three more months complete remission was achieved. Grade 4 neutropaenia was reported once during the treatment. The patient was temporarily reluctant to start treatment. Better cooperation was achieved after using psychotherapy. The following case confirms the impact of the patient’s mental condition on the treatmentinitiation. The possibility of obtaining long-term complete remission in advanced pancreatic cancer — a disease with poor prognosis — following the use of gemcitabine and nab-paclitaxel-containing chemotherapy is documented.

Get Citation

Keywords

complete response; pancreatic cancer; gemcitabine; nab-paclitaxel; depression

About this article
Title

Long-term complete remission of pancreatic cancer after first-line chemotherapy with gemcitabine and nab-paclitaxel in a patient with depressive disorder

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 2 (2020)

Article type

Case report

Pages

83-86

Published online

2020-05-15

DOI

10.5603/OCP.2020.0016

Bibliographic record

Oncol Clin Pract 2020;16(2):83-86.

Keywords

complete response
pancreatic cancer
gemcitabine
nab-paclitaxel
depression

Authors

Ewa Anna Kosakowska
Anna Cencelewicz-Lesikow
Jakub Pałucki
Michał Kunkiel
Agnieszka Jagiełło-Gruszfeld

References (13)
  1. Potemski P, Bujko K, Wyrwicz L. Nowotwory układu pokarmowego. In: Krzakowski M (ed.). Onkologia kliniczna. Via Medica, Gdańsk. 2016; II: 572–642.
  2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6): 2403–2413.
  3. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–1825.
  4. Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012; 13(5): 497–501.
  5. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691–1703.
  6. Boyd AD, Riba M. Depression and pancreatic cancer. J Natl Compr Canc Netw. 2007; 5(1): 113–116.
  7. Sato N, Hasegawa Y, Saito A, et al. Association between chronological depressive changes and physical symptoms in postoperative pancreatic cancer patients. Biopsychosoc Med. 2018; 12: 13.
  8. Carney CP, Jones L, Woolson RF, et al. Relationship between depression and pancreatic cancer in the general population. Psychosom Med. 2003; 65(5): 884–888.
  9. Parker G, Brotchie H. Pancreatic Cancer and Depression: A Narrative Review. J Nerv Ment Dis. 2017; 205(6): 487–490.
  10. Kenner BJ. Early Detection of Pancreatic Cancer: The Role of Depression and Anxiety as a Precursor for Disease. Pancreas. 2018; 47(4): 363–367.
  11. Barnes AF, Yeo TP, Leiby B, et al. Pancreatic cancer-associated depression: a case report and review of the literature. Pancreas. 2018; 47(9): 1065–1077.
  12. Zhou Yi, Gu X, Wen F, et al. Association of KRAS gene mutations with depression in older metastatic colorectal cancer patients. Int Psychogeriatr. 2016; 28(12): 2019–2028.
  13. Zeitouni D, Pylayeva-Gupta Y, Der CJ, et al. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel). 2016; 8(4): E45.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl